News GSK's growth plans dented by Blenrep setback FDA advisors have voted that the benefit/risk profile of GSK's multiple myeloma therapy, Blenrep, does not support its approval in the US.
News UK plan to lead life sciences gets mixed response The UK has unveiled its plan to revitalise the life sciences sector and become a global leader by 2030, but a pharma trade group says it falls short.
News Could a vaccine adjuvant be protective against dementia? Scientists behind a study suggesting GSK's RSV vaccine may be protective against dementia have said the adjuvant used in it may be responsible.
News EU kicks off review of GSK's linerixibat in PBC GSK's drug for severe itching in patients with autoimmune liver disease PBC is now under review in the EU and US, as Mirum Pharma tries to catch up.
News Moderna's RSV shot gets US nod for use in younger adults The label for Moderna's RSV vaccine mResvia has been expanded to include adults aged 18 and over in the US, but will that lead to an uptick in sales?
News NHS starts first national rollout of Blenrep for myeloma England is the first country in the world to make GSK's relaunched anti-BCMA drug Blenrep available to patients with multiple myeloma.